Realcan Pharmaceutical Group Co., Ltd.

XSEC:002589 Stock Report

Market Cap: CN¥4.8b

Realcan Pharmaceutical Group Past Earnings Performance

Past criteria checks 2/6

Realcan Pharmaceutical Group's earnings have been declining at an average annual rate of -11.5%, while the Healthcare industry saw earnings growing at 2% annually. Revenues have been declining at an average rate of 32.6% per year. Realcan Pharmaceutical Group's return on equity is 1%, and it has net margins of 0.5%.

Key information

-11.5%

Earnings growth rate

-12.0%

EPS growth rate

Healthcare Industry Growth7.0%
Revenue growth rate-32.6%
Return on equity1.0%
Net Margin0.5%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Realcan Pharmaceutical Group makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

XSEC:002589 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 247,9854076012
31 Mar 247,9801481515
31 Dec 238,0342084615
30 Sep 237,520-1,87389422
30 Jun 238,840-1,8591,26322
31 Mar 2310,291-1,8521,39421
01 Jan 2312,311-1,8311,66223
30 Sep 2214,321671,97315
30 Jun 2215,900752,25115
31 Mar 2219,389922,47714
01 Jan 2221,0601312,82612
30 Sep 2124,8511383,1108
30 Jun 2127,2442233,2887
31 Mar 2127,2352493,4118
31 Dec 2027,2342613,3249
30 Sep 2028,333-1,2573,36714
30 Jun 2030,002-1,1573,51512
31 Mar 2032,280-1,0243,73810
31 Dec 1935,259-9283,9927
30 Sep 1936,3075164,0440
30 Jun 1936,3685743,8700
31 Mar 1935,5316813,7420
31 Dec 1833,9197713,5150
30 Sep 1831,1961,1193,0980
30 Jun 1828,4081,0742,9350
31 Mar 1825,4449962,3760
31 Dec 1723,2941,0082,1200
30 Sep 1721,3819412,1390
30 Jun 1719,0948881,6620
31 Mar 1717,3557971,6700
31 Dec 1615,6195911,4040
30 Sep 1613,6024421,1520
30 Jun 1612,1673509530
31 Mar 1610,7972707790
31 Dec 159,7502366540
30 Sep 159,2222185570
30 Jun 158,7052054800
31 Mar 158,2411924090
31 Dec 147,7861813700
30 Sep 147,1271733030
30 Jun 146,6951622720
31 Mar 146,3221532450
31 Dec 135,9261442320

Quality Earnings: 002589 has high quality earnings.

Growing Profit Margin: 002589 became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 002589's earnings have declined by 11.5% per year over the past 5 years.

Accelerating Growth: 002589 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: 002589 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare industry (-5.7%).

Return on Equity

High ROE: 002589's Return on Equity (1%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 05:24
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Realcan Pharmaceutical Group Co., Ltd. is covered by 17 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yalei YanBohai Securities Co., Ltd.
Shuchang LiuChangjiang Securities Co. LTD.
Xu Qing LiuChasing Securities